1. Search Result
Search Result
Results for "

diabetics

" in MedChemExpress (MCE) Product Catalog:

821

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

11

Biochemical Assay Reagents

63

Peptides

1

MCE Kits

20

Inhibitory Antibodies

241

Natural
Products

40

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-66009
    Epalrestat
    5+ Cited Publications

    ONO2235

    Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat
  • HY-B1670A
    (-)-Isoproterenol hydrochloride
    1 Publications Verification

    Levisoprenaline hydrochloride; Proternol L hydrochloride

    Caspase TNF Receptor Metabolic Disease
    (-)-Isoproterenol (Levisoprenalinel) hydrochloride is the R-isomer of Isoproterenol. (-)-Isoproterenol hydrochloride can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol hydrochloride can be used for the study of diabetic retinopathy .
    (-)-Isoproterenol hydrochloride
  • HY-12883
    PF 05089771
    4 Publications Verification

    Sodium Channel Neurological Disease
    PF 05089771 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy .
    PF 05089771
  • HY-B0093A
    Benazepril hydrochloride
    2 Publications Verification

    CGS14824A

    Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Akt Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .
    Benazepril hydrochloride
  • HY-121401A

    (1R)-(−)-Myrtenal; (−)-(1R,5S)-Myrtenal

    Akt Metabolic Disease Cancer
    (-)-Myrtenal ((1R)-(-)-Myrtenal) is an orally active terpene with antitumour activity. (-)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats .
    (−)-Myrtenal
  • HY-B1392
    Esmolol hydrochloride
    3 Publications Verification

    Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride
  • HY-14447

    Histamine Receptor Inflammation/Immunology Endocrinology
    Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system .
    Bilastine
  • HY-17374
    Benfotiamine
    1 Publications Verification

    S-Benzoylthiamine O-monophosphate

    SARS-CoV HIV Infection Metabolic Disease Inflammation/Immunology
    Benfotiamine (S-Benzoylthiamine O-monophosphate) is a vitamin B1 derivative that exhihibits potent antioxidative and anti-inflammatory activity. Benfotiamine can be used for the research of various secondary diabetic complications. Benfotiamine also can be used in infectious diseases such as HIV and COVID-19 .
    Benfotiamine
  • HY-128700
    Nicotinic acid mononucleotide
    1 Publications Verification

    Endogenous Metabolite Sirtuin Neurological Disease Inflammation/Immunology Cancer
    Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide
  • HY-19687
    Zopolrestat
    1 Publications Verification

    CP73850

    Aldose Reductase Metabolic Disease
    Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications .
    Zopolrestat
  • HY-103290

    Bradykinin Receptor Others
    R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice .
    R715
  • HY-N2555
    Tilianin
    2 Publications Verification

    Others Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Tilianin is an active flavonoid glycoside found in many medical plants, with potential anti-hypertensive, myocardial-protective, anti-diabetic, anti-hyperlipidemic, anti-inflammatory and antioxidant effects .
    Tilianin
  • HY-P11069

    Biochemical Assay Reagents Metabolic Disease
    Kidney-targeting peptide is a kidney-targeting peptide (KTP). Kidney-targeting peptide significantly enhances the renal targeting ability of Isoquercitrin (HY-N1445). Kidney-targeting peptide can be used in diabetic nephropathy research .
    Kidney-targeting peptide
  • HY-112482
    ABT-702
    3 Publications Verification

    Adenosine Kinase Adenosine Receptor Neurological Disease Inflammation/Immunology
    ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research .
    ABT-702
  • HY-164781
    KOTX1
    1 Publications Verification

    MBE1

    Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .
    KOTX1
  • HY-B0093
    Benazepril
    2 Publications Verification

    CGS14824A free base

    Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .
    Benazepril
  • HY-15314
    Ranirestat
    1 Publications Verification

    AS-3201

    Aldose Reductase Neurological Disease Metabolic Disease
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas .
    Ranirestat
  • HY-112482A
    ABT-702 hydrochloride
    3 Publications Verification

    Adenosine Kinase Adenosine Receptor Neurological Disease Inflammation/Immunology
    ABT-702 hydrochloride is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 hydrochloride shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 hydrochloride attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 hydrochloride shows analgesic and anti-inflammatory effects in vivo. ABT-702 hydrochloride can be used for diabetic retinopathy research .
    ABT-702 hydrochloride
  • HY-18967

    AT-001; Aldose reductase-IN-1

    Aldose Reductase Metabolic Disease
    Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy .
    Caficrestat
  • HY-117623

    PF-249

    AMPK Metabolic Disease
    PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC50 of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 improves renal function in ZSF-1 rats with diabetic nephropathy. PF-06685249 can be used for diabetic nephropathy research .
    PF-06685249
  • HY-14791
    Ibipinabant
    1 Publications Verification

    SLV319; BMS-646256

    Cannabinoid Receptor Metabolic Disease
    Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .
    Ibipinabant
  • HY-128442

    Phenyl hydrogen sulfate

    Endogenous Metabolite Metabolic Disease
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease .
    Phenyl sulfate
  • HY-N2531

    Autophagy Cardiovascular Disease
    Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .
    Notoginsenoside Fc
  • HY-10655
    Palosuran
    4 Publications Verification

    ACT-058362

    Urotensin Receptor Cardiovascular Disease
    Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .
    Palosuran
  • HY-124373

    MMP Metabolic Disease
    ND-336 is a selective inhibitor of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-14, with Kis of 85, 150, and 120 nM, respectively. ND-336 accelerates diabetic wound healing in mice by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound .
    ND-336
  • HY-W166297
    Esculin sesquihydrate
    5 Publications Verification

    p38 MAPK Cancer
    Esculin sesquihydrate, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin sesquihydrate ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts anti?oxidative stress and anti?inflammatory effects, via the MAPK signaling pathway .
    Esculin sesquihydrate
  • HY-W011240

    Methforylthiazidine; Rontyl

    Sodium Channel Chloride Channel Metabolic Disease Endocrinology
    Hydroflumethiazide (Methforylthiazidine) is an orally active and potent thiazide diuretic. Hydroflumethiazide possesses the ability to directly stimulate A cell secretion in the normal and alloxan diabetic pancreas .
    Hydroflumethiazide
  • HY-P2217

    DSC-127; NorLeu3-A(1-7)

    Angiotensin Receptor Inflammation/Immunology
    Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers .
    Aclerastide
  • HY-116239
    Zenarestat
    1 Publications Verification

    Aldose Reductase Neurological Disease Metabolic Disease
    Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .
    Zenarestat
  • HY-106246

    EMD 281014 free base; LY 2422347

    5-HT Receptor Neurological Disease Metabolic Disease
    Pruvanserin (EMD 281014 free base) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia .
    Pruvanserin
  • HY-105946

    Interleukin Related NADPH Oxidase Cardiovascular Disease Metabolic Disease
    Hidrosmin, a flavonoid, is derived from Diosmin (HY-N0178). hidrosmin exerts a beneficial effect against diabetic nephropathy (DN) by reducing inflammation, oxidative stress, and senescence pathways. Hidrosmin can be used for the research of venous insufficiency and diabetes mellitus .
    Hidrosmin
  • HY-P1131

    Neuropeptide Y Receptor Cardiovascular Disease
    M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .
    M617
  • HY-119678
    Fortunellin
    1 Publications Verification

    AMPK Keap1-Nrf2 Cardiovascular Disease Metabolic Disease
    Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing AMPK/Nrf2 pathway. Fortunellin can be used for diabetic cardiomyopathy research .
    Fortunellin
  • HY-66009R

    ONO2235 (Standard)

    Reference Standards Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat (Standard)
  • HY-164368

    Phosphodiesterase (PDE) Insulin Receptor Metabolic Disease
    GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation .
    GLUT4 activator 2
  • HY-162325

    Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy Metabolic Disease
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .
    WJ-39
  • HY-128700A

    Endogenous Metabolite Sirtuin Metabolic Disease
    Nicotinic acid mononucleotide triethylamine acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide triethylamine exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide triethylamine reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide triethylamine is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide triethylamine
  • HY-19876

    Debio-0827

    Opioid Receptor Aminopeptidase Neprilysin Neurological Disease Metabolic Disease
    PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED50 value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain .
    PL37
  • HY-W662576

    Kallikrein Cardiovascular Disease Metabolic Disease Endocrinology
    KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research .
    KVD-001
  • HY-106915

    SPR 210

    Aldose Reductase Neurological Disease Metabolic Disease
    SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753)-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications .
    SG-210
  • HY-134191

    Cryptochrome Metabolic Disease
    Cryptochrome modulator 1 (Compound 50) is a cryptochrome modulator. Cryptochrome modulator 1 reduces glucose intolerance in diabetic mice .
    Cryptochrome modulator 1
  • HY-B1670

    Levisoprenalinel; Proternol L

    Caspase TNF Receptor Metabolic Disease
    (-)-Isoproterenol (Levisoprenalinel) is the R-isomer of Isoproterenol. (-)-Isoproterenol can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol can be used for the study of diabetic retinopathy .
    (-)-Isoproterenol
  • HY-142693

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    Angiogenesis agent 1 (compound C-31) is a salidroside-derivated glycoside analogue. Angiogenesis agent 1 is an activator of the HIF-1α pathway. Angiogenesis agent 1 has the potential for the research of diabetic hind limb ischemia .
    Angiogenesis agent 1
  • HY-124373A

    MMP Metabolic Disease
    (R)-ND-336 is a potent and selective MMP-9 inhibitor with a Ki of 19 nM. (R)-ND-336 inhibits MMP-2 (Ki=127 nM) and MMP-14 (Ki=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research .
    (R)-ND-336
  • HY-178780

    GPR119 Metabolic Disease
    MKP10241 is an orally active GPR119 agonist. MKP10241 elevates cAMP levels in the GPR119 expressing cell line (EC50: 3.7 nM). MKP10241 reduces blood glucose levels and HbA1c in acute models and a chronic diabetic mouse model. MKP10241 also demonstrates excellent preclinical efficacy in acute as well as chronic rodent models of obesity, and MASH .
    MKP10241
  • HY-P991415

    AM712

    VEGFR Tie Others
    ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
    ASKG-712
  • HY-143476

    Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-N12313

    Aldose Reductase Metabolic Disease
    Corybulbine, an alkaloid that can be isolated from the methanolic extract of Corydalis ternata, is an aldose reductase (ALR2) inhibitor. Corybulbine can be used for diabetic complications research .
    Corybulbine
  • HY-10383

    Endothelin Receptor Cardiovascular Disease Metabolic Disease
    J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications [1][3].
    J-104132
  • HY-100819

    CCR Metabolic Disease
    RO5234444 is an orally active CCR2 antagonist, with IC50s of 22nM for human CCR2 and 161 nM for mouse CCR2. RO5234444 alleviates glomerulosclerosis, reduces albuminuria, and significantly improves the glomerular filtration rate (GFR) in the uninephrectomized (1K) type 2 diabetic db/db mouse model. RO5234444 can be used for the study of type 2 diabetic nephropathy .
    RO5234444

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: